000			05245nam a22005055i 4500
001			978-4-431-55582-7
003			DE-He213
005			20160615101158.0
007			cr nn 008mamaa
008			150928s2016 ja | s |||| 0|eng d
020			_a9784431555827 _9978-4-431-55582-7
024	7		_a10.1007/978-4-431-55582-7 _2doi
049			_aAlfaisal Main Library
050		4	_aRC705-779
072		7	_aMJL _2bicssc
072		7	_aMED079000 _2bisacsh
082	0	4	_a616.2 _223
245	1	0	_aIdiopathic Pulmonary Fibrosis _h[electronic resource] : _bAdvances in Diagnostic Tools and Disease Management / _cedited by Hiroyuki Nakamura, Kazutetsu Aoshiba.
250			_a1st ed. 2016.
264		1	_aTokyo : _bSpringer Japan : _bImprint: Springer, _c2016.
300			_aX, 259 p. 96 illus., 30 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aPart 1 -- Definition, epidemiology, and pathogenesis -- Chapter 1: Definition of IPF  (Question: Is the latest classification [ATS/ERS] satisfactory?) -- Chapter 2: Epidemiology and risk factors of IPF  (Question: Can we dare to ask, “What are the possible causes?”) -- Chapter 3: Acute exacerbation of IPF  (Question: The concept was proposed in Japan, but why was it not recognized in western countries?) -- Chapter 4: Pathogenesis   (Question: Is abnormal repair of epithelial damage involved in the basic pathogenesis of this disease?) -- Part 2 Diagnosis    -- Chapter 5: Specific serum markers of IPF  (Question: What are the significances of KL-6, SP-A, and SP-D?) -- Chapter 6: High-resolution CT of honeycombing and IPF/UIP  (Question: To what extent can honeycomb lung be diagnosed by imaging? To what extent can IPF diagnosis be made by HRCT?) -- Chapter 7: Pathology of IPF  (Question: Why does the pathological classification of IIPs vary among pathologists?) -- Chapter 8: Differential diagnosis  (Question: What should we particularly keep in mind in the differential diagnosis?) -- Part 3 Management and prognosis    -- Chapter 9 Pharmacotherapy of IPF (antifibrotic compounds)  (Question: Can antifibrotic agents really inhibit fibrosis? How about the development of new therapeutic agents?) -- Chapter 10: Pharmacotherapy of IPF (Corticosteroids, immunosuppressants)  (Question: Are these actually effective? Ineffective? Harmful?) -- Chapter 11: Non-pharmacological therapy for IPF  (Question: Is respiratory care actually effective?) -- Chapter 12: Pharmacotherapy of acute exacerbation of IPF (Corticosteroids, immunosuppressants and direct hemoperfusion with polymyxin B)  (Question: Are high-dose steroid therapy, other immunosuppressant therapy, and PMX therapy [often used in Japan] really effective?) -- Part 4 Topics    -- Chapter 13 :Combined pulmonary fibrosis and emphysema (CPFE)  (Question: Is it an independent disease entity?) -- Chapter 14: Common pathways in IPF and lung cancer  (Question: Why is lung cancer associated with IPF at a high frequency?) -- Chapter 15 :Acute exacerbation of IIPs after pulmonary resection for lung cancer   (Question: Can acute exacerbation of IPF be predicted preoperatively?)           .
520			_aFrom epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF). A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IIP sufferers develop lung cancer.
650		0	_aMedicine.
650		0	_aRespiratory organs _xDiseases.
650		0	_aCytokines.
650		0	_aGrowth factors.
650	1	4	_aMedicine & Public Health.
650	2	4	_aPneumology/Respiratory System.
650	2	4	_aCytokines and Growth Factors.
655		7	_aElectronic books. _2local
700	1		_aNakamura, Hiroyuki. _eeditor.
700	1		_aAoshiba, Kazutetsu. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9784431555810
856	4	0	_uhttp://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1007/978-4-431-55582-7
912			_aZDB-2-SME
942			_2lcc _cEBOOKS
999			_c260614 _d260614